PROTAC’ing oncoproteins: targeted protein degradation for cancer therapy

Molecularly targeted cancer therapies substantially improve patient outcomes, although the durability of their effectiveness can be limited. Resistance to these therapies is often related to adaptive changes in the target oncoprotein which reduce binding affinity. The arsenal of targeted cancer ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Kelm, Jeremy M., Pandey, Deepti S., Malin, Evan, Kansou, Hussein, Arora, Sahil, Kumar, Raj, Gavande, Navnath S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10061819/
https://www.ncbi.nlm.nih.gov/pubmed/36991452
http://dx.doi.org/10.1186/s12943-022-01707-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10061819/
https://www.ncbi.nlm.nih.gov/pubmed/36991452
http://dx.doi.org/10.1186/s12943-022-01707-5

Ejemplares similares